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Introduction {#sec001}
============

Chronic infection with the eukaryotic parasite *Toxoplasma gondii* results in the recruitment of activated, Th1-polarized T cells to brain that contribute to control of the parasite and promote long-term host survival \[[@pone.0228251.ref001]--[@pone.0228251.ref004]\]. Though it has been well established that T cells play an essential role in the inflammatory immune response that restricts the replication and spread of the parasite in the brain, regulatory mechanisms that limit this inflammation are equally important in long-term host survival. Immunosuppressive cytokines such as IL-10 and IL-27 have been shown to be required in the chronic phase of infection to limit excessive inflammatory cytokine production and T cell proliferation, both of which can lead to fatal immunopathology in mice lacking IL-10 or IL-27 signaling \[[@pone.0228251.ref005]--[@pone.0228251.ref007]\]. Regulatory T cells (Tregs) have also been implicated as an important player in limiting T cell responses during infection with *T*. *gondii*. During the acute stage of infection, increasing Treg numbers using treatment with IL-2 complexes resulted in decreased inflammation and immunopathology in the small intestine and liver, but was associated with increased parasite burden in the brain in the later stage of infection \[[@pone.0228251.ref008]\]. Furthermore, the recruitment and persistent presence of Tregs in the inflamed brain during the chronic stage of infection \[[@pone.0228251.ref009]\] suggests that this regulatory population could serve as an important means of limiting excessive inflammation in the CNS. The signals that serve to maintain the Treg population during the course of infection with *T*. *gondii*, however, are still being elucidated.

ICOS (inducible T cell costimulator) is one of a multitude of costimulatory molecules that has been shown to be important for optimal immune response to infections \[[@pone.0228251.ref010]--[@pone.0228251.ref013]\]. In particular, ICOS has been implicated in a wide array of immune functions, including the development of Tfh cells and formation of germinal centers that allows for optimal class-switched antibody production \[[@pone.0228251.ref014]--[@pone.0228251.ref017]\], as well as effector T cell proliferation and cytokine production \[[@pone.0228251.ref018]--[@pone.0228251.ref022]\]. ICOS does not only promote inflammatory T and B cell responses, however. More recently, ICOS has been shown to promote immune regulation rather than inflammation, either through supporting the survival and suppressive cytokine production of Tregs \[[@pone.0228251.ref023]--[@pone.0228251.ref027]\] or through promoting turnover of effector T cells through inhibiting IL-2 signaling \[[@pone.0228251.ref007]\]. These seemingly contradictory roles for a single costimulatory molecule emphasize the need to better understand the inflammatory context in which ICOS is playing a role, as well as how downstream signaling events following ICOS ligation are integrated in different cell T cell populations.

During the early acute stage of infection with *T*. *gondii*, ICOS KO mice have been reported to have sub-optimal T cell proliferation and IFN-γ production, though these mice were still able to control the parasite and survive to the later stages of infection \[[@pone.0228251.ref028]\]. In this case ICOS seems to play a redundant role with its family member CD28, as ICOS KO mice were only more susceptible to the infection on a CD28 KO background \[[@pone.0228251.ref028]\].We sought to further characterize the complex role of ICOS both at baseline and during chronic *T*. *gondii* infection in the CNS using two models of ICOS deficiency. We utilized a complete ICOS KO mouse, which lacks expression of ICOS on the surface of T cells and therefore lacks all signaling pathways downstream of ICOS, and ICOS Y^181^F mice (hereby referred to as ICOS YF), which express normal levels of ICOS on the surface of T cells, but contain a tyrosine to phenylalanine mutation in the cytoplasmic tail of ICOS that prevents the recruitment and activation of PI3K \[[@pone.0228251.ref029]\]. We found that both ICOS KO and ICOS YF mice had baseline defects in maintaining Treg frequencies in the spleen, leading to skewed Teff:Treg ratios during homeostasis and in the absence of overt inflammation.

During chronic *T*. *gondii* infection, direct comparison of ICOS KO and ICOS YF mice to WT mice showed that both forms of ICOS deficiency resulted in severe defects in production of parasite-specific IgG, which correlated with higher parasite burdens in the brains of ICOS KO and ICOS YF mice compared to controls. Conversely, both ICOS KO and ICOS YF mice had expanded effector T cell populations in the spleen and brain during chronic infection compared to WT mice. This expansion of effector T cells correlated with a partial loss of Tregs in the spleens and brains of ICOS KO and ICOS YF mice. Interestingly, the remaining Tregs in the brains of ICOS KO and ICOS YF mice displayed distinct phenotypes with regards to several Treg identity markers. Though both genotypes showed a similar decrease in Treg frequency in the brain, the remaining ICOS KO Tregs still expressed WT levels of Foxp3 and CD25. The remaining ICOS YF Tregs in the brain, on the other hand, had significantly decreased expression of both Foxp3 and CD25 compared to ICOS KO or WT Tregs. PI3K has long been assumed to be the major downstream signaling pathway activated with ICOS ligation, but these results suggest that PI3K-independent signaling pathways may be involved in shaping the Treg response during inflammation.

Materials and methods {#sec002}
=====================

Mice and infection model {#sec003}
------------------------

C57BL/6 WT mice were purchased from Jackson laboratories to be used for age- and sex-matched controls. ICOS KO \[[@pone.0228251.ref030]\] and ICOS Y^181^F (ICOS YF) \[[@pone.0228251.ref029]\] mice were kindly shared by Dr. Daniel Campbell from the Department of Immunology, University of Washington. ICOS KO and ICOS YF mice were then kept and bred in University of Virginia specific pathogen-free facilities, and were age- and sex-matched for experiments. All experimental procedures followed regulations set by the Institutional Animal Care and Use Committee at the University of Virginia. All infections used the type II parasite *Toxoplasma gondii* (strain Me49), which were maintained in chronically infected Swiss Webster mice (purchased from Charles River) and passaged through CBA/J mice (purchased from Jackson Laboratories) before experimental infections in C57BL/6, ICOS KO, and ICOS YF mice. For experimental infections, the brains of chronically infected (4 to 8 weeks) CBA/J mice were homogenized to isolate tissue cysts containing parasite. Experimental mice were then injected intraperitoneally with 10 to 20 parasite cysts.

Tissue and blood processing {#sec004}
---------------------------

Chronically infected mice (5--6 weeks post infection) were sacrificed and perfused with 40 mL 1x PBS. Perfused brains and spleens were then put into cold complete RPMI (cRPMI) (10% fetal bovine serum, 1% NEAA, 1% pen/strep, 1% sodium pyruvate, 0.1% β-mercaptoethanol). Brains were then minced and passaged through an 18-gauge needle, and enzymatically digested using 0.227mg/mL collagenase/dispase and 50U/mL DNase (Roche) for 1 hour at 37°C. Following enzymatic digestion, brain homogenate was passed through a 70 μm filter (Corning). To remove myelin and obtain a single cell suspension, filtered brain homogenate was resuspended in 40% percoll and spun at 650g for 25 minutes. Myelin was then aspirated and cells were washed with cRPMI and counted on a hemocytometer. Spleens were homogenized and filtered through a 40 μm filter (Corning). Red blood cells were then lysed using 2 mL RBC lysis buffer (0.16 M NH~4~Cl). Following RBC lysis, spleen cells were then washed with cRPMI and resuspended for counting on a hemocytometer.

For experiments in which blood serum was collected, mice were sacrificed and the right atrium of the heart was cut to prepare for perfusion. Prior to perfusion, 300 μL of blood was taken from the chest cavity. To separate serum, blood samples were allowed to clot overnight at 4°C. Blood samples were then spun at 14,000rpm for 10 minutes to fully separate clotted blood pellet from serum. Serum was stored at -80°C until further analysis was performed.

Flow cytometry {#sec005}
--------------

Following tissue processing, single cell suspensions from brains and spleens were plated in a 96-well U-bottom plate. Cells were first incubated with 50 μL Fc block (1μg/mL 2.4G2 Ab (BioXCell), 0.1% rat gamma globulin (Jackson Immunoresearch)) for 10 minutes at room temperature. Cells were then surface stained for CD3 (145-2C11), CD25 (PC61), CD8 (S3-6.7), CD4 (GK1.5), CD19 (eBio1D3), NK1.1 (PK136), MHCII (M5/114.15.2), CD11c (N418), CD80 (16-10A1), CD86 (GL1), CD45 (30-F11), CD11b (M1/70), and a live/dead stain for 30 minutes at 4°C. After surface staining, cells were washed with FACS buffer (1% PBS, 0.2% BSA, and 2mM EDTA) and fixed at 4°C overnight with a fixation/permeabilization kit (eBioscience) or 2% PFA. After overnight fixation, cells were permeabilized and stained for intracellular markers Bcl-2 (3F11) and Foxp3 (FJK-16S) for 30 minutes at 4°C. Cells were then washed with FACS buffer, resuspended, and run on a Gallios flow cytometer (Beckman Coulter). All analysis was done using Flowjo software, v.10.

ELISA {#sec006}
-----

ELISAs for parasite-specific IgG were performed as previously described \[[@pone.0228251.ref031]\]. Briefly, Immunolon 4HBX ELISA plates (Thermofisher) were coated overnight at 4°C with 5 μg soluble *Toxoplasma* antigen (STAg) diluted in 1X PBS. Following antigen coating, plates were washed with 1x PBS with 0.1% Triton and 0.05% Tween, then a blocking step was performed using 10% FBS for 2 hours at room temperature. After washing, serial dilutions of serum were added to plate wells overnight at 4°C. Following incubation with serum samples, plates were washed as described above and wells were incubated with goat α-mouse IgG, human ads-HRP (Southern Biotechnology) for 1 hour at room temperature. Finally, ABTS peroxidase substrate solution (KBL) was added. Immediately after a color change occurred plates were read on an Epoch BioTek plate reader using Gen5 2.00 software.

Parasite cyst counts {#sec007}
--------------------

After mincing with a razor blade and before enzymatic digestion, brain tissue was passed through an 18- and 22-gauge needle. 30 μL of brain homogenate was then placed onto a microscope slide (VWR) and cysts were counted using a brightfield DM 2000 LED microscope (Leica).

Statistical analysis {#sec008}
--------------------

Statistical analysis comparing two or three different groups at a single time point was performed in Prism software (v. 7.0a) using a Student's t test or one-way ANOVA, respectively. When data from multiple experiments were combined, a randomized block ANOVA was used in R v.3.4.4 statistical software to account for natural variability between experimental dates by modeling the genotype (WT vs. ICOS KO vs. ICOS YF) as a fixed effect and the experimental date as a random effect. The particular test used for each individual panel shown, as well as the group size, is specified in each figure legend. P values are displayed as follows: ns = not significant, \* p\<0.05, \*\* p\<0.01, \*\*\* p\<0.001. All data were graphed using Prism software and are presented as the mean ± standard deviation unless otherwise noted in the figure legend.

Results {#sec009}
=======

ICOS KO and ICOS YF mice chronically infected with T. gondii have increased numbers of effector T cells in the brain as well as increased expression of CD25 {#sec010}
------------------------------------------------------------------------------------------------------------------------------------------------------------

The signals involved in the ongoing T cell response in the brain during chronic infection with *T*. *gondii* are still being elucidated. One such signal, ICOS, has previously been shown to play a costimulatory role early in the infection during T cell priming \[[@pone.0228251.ref018], [@pone.0228251.ref028]\]. In the chronic stage of infection, however, ICOS takes on a regulatory role by limiting effector T cells in the brain \[[@pone.0228251.ref007]\]. Furthermore, other models of inflammation have suggested additional roles for ICOS signaling in other areas of the immune response, namely the generation of Tfh cells \[[@pone.0228251.ref017], [@pone.0228251.ref032]--[@pone.0228251.ref034]\] and the promotion of regulatory T cell activity \[[@pone.0228251.ref023], [@pone.0228251.ref025]\]. During a chronic infection that requires ongoing inflammation however, the seemingly complex and time-dependent role of ICOS remains to be fully described. In order to further elucidate the role of ICOS signaling during chronic infection, we utilized two genetic models of ICOS deficiency: total ICOS KO mice, which lack expression of ICOS on the cell surface and subsequently all downstream signaling pathways, and ICOS YF mice, which maintain wild-type levels of ICOS expression but contain a mutation in the cytoplasmic tail of ICOS that prevents activation of its major downstream signaling pathway PI3K \[[@pone.0228251.ref029], [@pone.0228251.ref035]\].

Given previous results suggesting that the loss of ICOS signaling exclusively in the chronic phase of infection leads to increased expansion of effector T cells in the inflamed brain \[[@pone.0228251.ref007]\], we hypothesized that genetic loss of ICOS expression of ICOS-mediated PI3K signaling would result in increased numbers of T cells in the brain during chronic infection. Indeed, both ICOS KO and ICOS YF mice had increased numbers of CD4^+^ and CD8^+^ effector T cells in the brain during chronic infection compared to WT mice ([Fig 1A](#pone.0228251.g001){ref-type="fig"}). Neither ICOS KO nor ICOS YF mice had a deficiency in expression of costimulatory molecules CD80 and CD86 on myeloid cells recruited to the brain during chronic infection ([Fig 1B](#pone.0228251.g001){ref-type="fig"}), suggesting that the increased accumulation of effector T cells in the brains of ICOS KO and ICOS YF mice was not a result of increased costimulation provided to T cells from antigen-presenting cells. Rather, the increased number of effector T cells correlated with increased expression of CD25 on the surface of effector CD4^+^ and CD8^+^ T cells in the brain ([Fig 1C--1F](#pone.0228251.g001){ref-type="fig"}), which is consistent with previously published results examining the effects of ICOS blockade only in the chronic phase of infection \[[@pone.0228251.ref007]\]. Increased expression of the survival factor Bcl-2 following antibody-mediated blockade of ICOS in the chronic phase of infection has previously been implicated as a mechanism supporting increased survival of effector T cell populations in the inflamed brain \[[@pone.0228251.ref007]\]. Interestingly, the increased number of effector T cells in the brains of ICOS KO and ICOS YF mice correlated with an increase in Bcl-2 expression in only the CD4^+^ effector T cell population compared to WT mice, though no increase in Bcl-2 expression in the CD8^+^ effector T cell population was observed ([Fig 1G--1I](#pone.0228251.g001){ref-type="fig"}), suggesting a differential effect of the genetic loss of ICOS or ICOS-mediated PI3K signaling on the CD4^+^ and CD8^+^ T cell populations in the inflamed brain. Taken together, these data suggest that a genetic loss of ICOS or ICOS-mediated PI3K signaling leads to the expansion of CD4^+^ and CD8^+^ effector T cells in the brain during chronic infection, supporting previously published results implicating an intrinsic inhibitory role for ICOS signaling on T cells in the inflamed brain.

![ICOS KO and ICOS YF mice chronically infected with *T*. *gondii* have increased numbers of effector T cells in the brain as well as increased expression of CD25.\
WT, ICOS KO, and ICOS YF mice were infected with *T*. *gondii*. 5 weeks post-infection, brain mononuclear cells (BMNC) were isolated and analyzed by flow cytometry. **(A)** Total numbers of effector CD4+ T cells (CD4+Foxp3-) and effector CD8+ T cells isolated from the brain (n = 3--5 per group, data is pooled from three independent experiments and analyzed by randomized block ANOVA). **(B)** Mean fluorescence intensity (MFI) of CD80 and CD86 on macrophages and DCs isolated from the brain. DCs were pre-gated on live CD45+CD19-NK1.1-CD3-MHCIIhiCD11c+ and macrophages (Mac) were pre-gated on CD45+CD19-NK1.1-CD3-CD11b+MHCIIhi/low (n = 4--5 per group, data is representative of two independent experiments and analyzed by randomized block ANOVA). Representative flow plots and quantification of CD25+ CD4+ effector T cells **(C-D)** and CD8+ effector T cells **(E-F)** (n = 3--5 per group, data is pooled from three independent experiments and analyzed by randomized block ANOVA). Representative histograms of Bcl-2 expression of CD4+ effector T cells **(G)** and CD8+ effector T cells **(H)**. **(I)** MFI of Bcl-2 on effector CD4+ and CD8+ T cells in the brain (n = 4--5 per group, data is representative of three independent experiments and analyzed by one-way ANOVA). ns denotes not significant, \* denotes p\<0.05, \*\* denotes p\<0.01, \*\*\* denotes p\<0.001 and \*\*\*\* denotes p\<0.0001 for all panels.](pone.0228251.g001){#pone.0228251.g001}

The accumulation of effector T cells in the brains of ICOS KO and ICOS YF mice during chronic infection suggests a loss of regulation of the ongoing effector T cell response, could be due to an intrinsic effect of the loss of ICOS signaling in the effector T cells themselves as previously described \[[@pone.0228251.ref007]\]. However, the loss of regulation and subsequent expansion of effector T cell populations observed in ICOS KO and ICOS YF mice could also be explained by a lack of Treg-mediated suppression of T cell responses in the inflamed brain. ICOS has been shown to be important for Treg survival and maintenance of an activated, effector Treg population during both homeostasis and in models of inflammation \[[@pone.0228251.ref013], [@pone.0228251.ref023]--[@pone.0228251.ref027]\]. Therefore, we assessed the basic phenotype of the Treg population in the inflamed brain during chronic *T*. *gondii* infection in ICOS KO and ICOS YF mice. We observed a similar decrease in the frequency of Tregs in the brains of ICOS KO and ICOS YF mice, as both genotypes presented with about half the frequency of Tregs in the brain as WT controls ([Fig 2A--2D](#pone.0228251.g002){ref-type="fig"}), though total Treg numbers were not decreased ([Fig 2E](#pone.0228251.g002){ref-type="fig"}). Interestingly, however, of the Tregs that were found in the brain during chronic *T*. *gondii* infection, WT and ICOS KO Tregs maintained equivalent levels of Foxp3 expression, yet ICOS YF Tregs in the brain had significantly decreased levels of Foxp3 expression compared to both WT and ICOS KO Tregs ([Fig 2F](#pone.0228251.g002){ref-type="fig"}). Foxp3 expression has been previously shown to regulate expression of the high affinity IL-2Rα chain (CD25) \[[@pone.0228251.ref036], [@pone.0228251.ref037]\], and both Foxp3 and CD25 are required for the development and maintenance of a suppressive regulatory T cell population \[[@pone.0228251.ref038]--[@pone.0228251.ref041]\]. Given the decreased expression of Foxp3 in ICOS YF Tregs, we also assessed the expression of CD25 on the Treg population in the inflamed brain during chronic infection. Similar to the decreased expression of Foxp3, we observed significantly lower levels of CD25 expression on ICOS YF Tregs in the brain compared to Tregs from WT or ICOS KO mice ([Fig 2G and 2H](#pone.0228251.g002){ref-type="fig"}).

![ICOS KO and ICOS YF mice have distinct Treg defects in the brain during chronic *T*. *gondii* infection.\
Immune cells were isolated from the brains **(A-H)** and spleens **(I-L)** of chronically infected WT, ICOS KO, and ICOS YF mice and analyzed by flow cytometry. **(A-C)** Representative flow cytometry plots are shown indicating the decrease in Treg frequency in the brain observed in ICOS KO and ICOS YF mice during chronic infection. **(D)** Total Treg frequency in the brain (n = 3--5 per group, data is pooled from three independent experiments and analyzed by randomized block ANOVA). **(E)** Treg number in the brains of WT, ICOS KO, and ICOS YF mice (n = 3--5 per group, data is pooled from three independent experiments and analyzed by randomized block ANOVA). **(F)** MFI of Foxp3 in the Treg population isolated from the brain during chronic infection (n = 4--5 per group, data is representative of three independent experiments and analyzed by one-way ANOVA). **(G)** The frequency of CD25+ Tregs in the brain (n = 3--5 per group, data is pooled from three independent experiments and analyzed by randomized block ANOVA). **(H)** MFI of CD25 on CD25+ Tregs in the brain (n = 4--5 per group, data is representative of three independent experiments and analyzed by one-way ANOVA). **(I)** The frequency of Tregs among the CD4+ population in the spleen during chronic infection (n = 3--5 per group, data is pooled from three independent experiments and analyzed using randomized block ANOVA). **(J)** The MFI of Foxp3 on Tregs in the spleen during chronic infection (n = 4--5 per group, data is representative of three independent experiments and analyzed using one-way ANOVA). **(K)** The frequency of CD25+ Tregs in the spleen during chronic infection (n = 3--5 per group, data is pooled from three independent experiments and analyzed by randomized block ANOVA). **(L)** MFI of CD25 on CD25+ Tregs in the brain (n = 4--5 per group, data is representative of three independent experiments and analyzed by one-way ANOVA). \* denotes p\<0.05, \*\* denotes p\<0.01, and \*\*\* denotes p\<0.001 for all panels.](pone.0228251.g002){#pone.0228251.g002}

To determine if the decrease in Foxp3 and CD25 expression was specifically found on ICOS YF Tregs in the inflamed brain, we also assessed the phenotype of Tregs found in the spleen at the same time point during chronic infection. Similar to the decreased Treg frequency observed in the chronically infected brain, we found a decreased frequency of Tregs in the spleens of both ICOS KO and ICOS YF mice during the same stage of chronic infection ([Fig 2I](#pone.0228251.g002){ref-type="fig"}). Unlike in the brain, however, the expression of Foxp3 on the remaining Tregs in the spleen was significantly decreased in both ICOS KO and ICOS YF mice compared to WT controls, though Foxp3 expression in ICOS YF Tregs in the spleen was decreased to a greater degree than that seen in ICOS KO Tregs ([Fig 2J](#pone.0228251.g002){ref-type="fig"}). Additionally, in contrast to the ICOS YF-specific defect in CD25 expression on Tregs found in the inflamed brain during chronic infection, both ICOS KO and ICOS YF Tregs in the spleen had an increased proportion of Tregs expressing CD25 ([Fig 2K](#pone.0228251.g002){ref-type="fig"}), though only ICOS KO Tregs in the spleen were expressing more CD25 than WT Tregs on a per-cell basis ([Fig 2L](#pone.0228251.g002){ref-type="fig"}). Overall, a partial loss of Treg frequency was observed in both ICOS KO and ICOS YF mice in both the brain and spleen during chronic infection. Interestingly though, the dynamics of Foxp3 and CD25 expression in ICOS KO and ICOS YF Tregs is distinct in different tissues. While ICOS YF Tregs had defects in both Foxp3 and CD25 expression on a per-cell basis in both the brain and the spleen, ICOS KO Tregs only had defects in Foxp3 expression in the spleen. These results suggest that, while ICOS expression is required for the maintenance of the Treg population in the inflamed brain and spleen, the ICOS YF mutation specifically leads to differences in retaining canonical Treg markers such as Foxp3 and CD25 in the brain during chronic infection.

Not only does ICOS play a role in effector and regulatory T cell responses, but ICOS signaling also plays a role in the development of Tfh cells, the formation of germinal centers, and the optimal production of class-switched antibody \[[@pone.0228251.ref014], [@pone.0228251.ref015], [@pone.0228251.ref017], [@pone.0228251.ref032], [@pone.0228251.ref042], [@pone.0228251.ref043]\]. Based on these previous reports, it was possible that ICOS KO and ICOS YF mice fail to produce adequate parasite-specific antibody during infection, therefore leading to increased parasite burdens in the brains of chronically infected animals. To address this question, we first looked for parasite-specific IgG levels in the serum of chronically infected WT, ICOS KO, and ICOS YF mice. Similar to what has been previously reported regarding antibody responses in ICOS KO and ICOS YF mice \[[@pone.0228251.ref029]\], both genotypes showed extremely diminished levels of circulating parasite-specific IgG in the serum during chronic infection compared to WT mice ([Fig 3A](#pone.0228251.g003){ref-type="fig"}). μMT mice that lack B cells succumb to *T*. *gondii* infection in the chronic stage with high parasite burdens found in the brain, suggesting that antibody responses are crucial in limiting parasite and promoting the long-term survival of mice infected with *T*. *gondii* \[[@pone.0228251.ref044]\]. We hypothesized that ICOS KO and ICOS YF mice, because of their inability to produce parasite-specific IgG, would also have defects in parasite control and increased parasite burdens in the brain during chronic infection. Indeed, both ICOS KO and ICOS YF mice had significantly increased parasite cyst burdens in the brain compared to WT controls ([Fig 3B](#pone.0228251.g003){ref-type="fig"}). This increase in cyst number was further shown in H&E stained histology sections from the brains of chronically infected WT, ICOS KO, and ICOS YF mice. Interestingly, while chronically infected WT mice usually have single parasite cysts in isolation from others, both ICOS KO and ICOS YF mice had and increased incidence of parasite cyst "clusters", where multiple cysts were found in close proximity to each other in the inflamed brain ([Fig 3C](#pone.0228251.g003){ref-type="fig"}). Taken together, these results suggest that ICOS KO and ICOS YF mice cannot produce sufficient parasite-specific class-switched antibody to control parasite, which is likely a contributing factor to the observed increase in parasite burden in the brains of chronically infected ICOS KO and ICOS YF mice compared to controls.

![ICOS KO and ICOS YF mice have severely impaired parasite-specific IgG antibody production and have increased cyst burden in the brain compared to WT infected mice.\
**(A)** Parasite-specific total IgG was measured by ELISA using serum from chronically infected WT, ICOS KO, and ICOS YF mice as well as naïve controls (n = 3--4 per group, data is representative of two independent experiments and analyzed using two-way ANOVA). **(B)** Total cyst numbers from the brains of chronically infected mice were enumerated by light microscopy (n = 3--4 per group, data is representative of two independent experiments and analyzed by one-way ANOVA). **(C)** Representative H&E stained sections from the brains of chronically infected WT, ICOS KO, and ICOS YF mice. White arrows indicated individual parasite cysts ranging in size. Scale bar is 50 μm. \*\* denotes p\<0.01, and \*\*\* denotes p\<0.001 for all panels.](pone.0228251.g003){#pone.0228251.g003}

Because ICOS KO and ICOS YF mice lack ICOS or ICOS-mediated PI3K signaling, respectively, from birth, it was possible that some of the reported T cell abnormalities, namely the expanded effector T cell populations and Treg defects, might be observed at baseline before the onset of inflammation. To address this, we analyzed the T cell populations in the spleen during homeostasis in adult WT, ICOS KO, and ICOS YF mice. Importantly, the baseline studies shown using ICOS KO and ICOS YF mice were performed on different experimental days, so direct comparison between ICOS KO and ICOS YF mice should not be made in this case. At baseline, ICOS KO and ICOS YF mice have a decreased frequency of Tregs in the spleen compared to their respective age-matched WT controls ([Fig 4A](#pone.0228251.g004){ref-type="fig"} and [Fig 4C](#pone.0228251.g004){ref-type="fig"}). Interestingly, of the Tregs isolated from the spleen, both ICOS KO and ICOS YF Tregs showed decreased levels of Foxp3 ([Fig 4B](#pone.0228251.g004){ref-type="fig"} and [Fig 4D](#pone.0228251.g004){ref-type="fig"}). These results are reminiscent of the decreased Foxp3 expression observed in ICOS KO and ICOS YF Tregs in the spleen during chronic infection ([Fig 2H](#pone.0228251.g002){ref-type="fig"}), though ICOS KO Tregs found in the inflamed brain expressed normal levels of Foxp3, while ICOS YF Tregs did not ([Fig 2E](#pone.0228251.g002){ref-type="fig"}). Taken together, these results suggest that the defects in Foxp3 expression in ICOS KO and ICOS YF Tregs in the spleen during chronic infection could stem from a baseline defect in Foxp3 expression present before any active inflammation.

![ICOS KO and ICOS YF mice have baseline defects in Foxp3 expression and Treg frequency, as well as expanded effector T cell populations in the spleen.\
**(A)** Representative flow plots showing the decrease in the frequency of Tregs in the spleens of ICOS KO compared to WT controls. **(B)** MFI of Foxp3 in Tregs in the spleen of uninfected WT and ICOS KO mice (n = 3 per group, data is representative of two independent experiments and analyzed by Student's t-test). **(C)** Representative flow plots showing the decrease in the frequency of Tregs in the spleens of ICOS YF mice compared to WT controls. **(D)** MFI of Foxp3 in Tregs in the spleen of uninfected WT and ICOS YF mice (n = 3 per group, data is representative of two independent experiments and analyzed by Student's t-test). **(E-F)** Immune cells were isolated from the spleens of ICOS KO **(E)** and ICOS YF **(F)** and T cell numbers were compared to WT controls (n = 3 per group, data is representative of two independent experiments and analyzed by Student's t-test). The Teff/Treg ratio in the spleen of uninfected mice was calculated in ICOS KO **(G)** and ICOS YF **(H)** mice (n = 3 per group, data is representative of two independent experiments and analyzed by Student's t-test).](pone.0228251.g004){#pone.0228251.g004}

To determine whether the Treg defects observed in ICOS KO and ICOS YF Tregs at baseline had any effects on the suppression of effector T cell populations, we enumerated effector T cells in the spleen as well. Interestingly, we observed significantly expanded effector T cell populations in the spleens of both ICOS KO and ICOS YF mice compared to their respective WT controls ([Fig 4E and 4F](#pone.0228251.g004){ref-type="fig"}). A skewed CD4^+^ effector T cell: Treg (Teff/Treg) ratio in the spleen was also already present at baseline in ICOS KO and ICOS YF mice, further suggesting a loss of regulation of the effector T cell populations in the spleen during homeostasis. Overall, these data suggest that ICOS KO and ICOS YF mice have similar defects in maintaining normal Treg frequencies and normal Foxp3 expression at baseline, though ICOS KO Tregs are able to maintain Foxp3 and CD25 expression in the inflamed brain during chronic infection, while ICOS YF Tregs are not. The differential effect on the expression of canonical Treg markers in ICOS KO and ICOS YF mice suggests that PI3K-independent signaling downstream of ICOS could play an essential role in maintaining Treg identity particularly during chronic inflammation.

Discussion {#sec011}
==========

Infection with the parasite *Toxoplasma gondii* leads to a chronic infection in immune-privileged sites such as the central nervous system \[[@pone.0228251.ref045]--[@pone.0228251.ref047]\]. As such, this chronic infection requires an exquisitely adapted inflammatory response that is capable of controlling the pathogen while also limiting immune-mediated pathology in the brain \[[@pone.0228251.ref048], [@pone.0228251.ref049]\]. Though many aspects of the inflammatory response to chronic *T*. *gondii* infection have been identified, here we describe a previously unknown multifaceted role for the costimulatory molecule ICOS (inducible T cell costimulator) in the context of chronic infection. Using two models of genetic deficiency in ICOS signaling, constitutive deficiency in ICOS expression (ICOS KO) and constitutive deficiency in ICOS-mediated PI3K signaling (ICOS YF), we found that both genotypes presented similar phenotypes in many aspects of the inflammatory response to *T*. *gondii* infection. We found that both ICOS KO and ICOS YF mice had similar defects in parasite-specific antibody production and parasite control in the brain, as well as defects in the maintenance of Treg frequency in both the spleen and brain during chronic infection. These results suggest that ICOS signaling plays many roles during the immune response to *T*. *gondii*, both promoting inflammation and parasite control, while also likely serving to limit inflammation by restricting effector T cell expansion and supporting the Treg population in both the inflamed brain and spleen.

One intriguing difference and paradoxical result observed in ICOS KO versus ICOS YF mice was found in the CNS Treg population. When directly compared during chronic infection, ICOS KO Tregs were able to maintain WT levels of Foxp3 and CD25, while ICOS YF Tregs in the inflamed brain were unable to sustain WT levels of both of these Treg markers. This difference in the maintenance of Foxp3 and CD25 expression in Tregs that completely lack ICOS expression and those that lack ICOS-mediated PI3K signaling is surprising, as PI3K has largely been reported to be the main downstream signaling molecule activated following ICOS ligation \[[@pone.0228251.ref010], [@pone.0228251.ref013], [@pone.0228251.ref035], [@pone.0228251.ref050]\]. The differential capacity to maintain Foxp3 and CD25 expression in ICOS YF Tregs compared to total ICOS KO Tregs suggests that different intracellular signaling events could be occurring when there is a complete loss of ICOS signaling versus when there is only a loss of ICOS-mediated PI3K signaling. This hypothesis is supported by one report showing that ICOS KO and ICOS YF effector T cells have a differential capacity to confer graft-versus host disease, as ICOS YF T cells were better able to potentiate TCR-mediated calcium flux than total ICOS KO T cells, thereby conferring worse inflammation and disease \[[@pone.0228251.ref051]\]. This study suggests that not only do PI3K-independent signaling pathways exist downstream of ICOS ligation, but that these pathways could play important roles in the process of inflammation, though the exact signaling pathways involved remain unknown in this context. More recently, a unique motif called IProx was identified in the cytoplasmic tail of ICOS, which was shown to recruit and activate the serine/threonine-protein kinase TBK1 \[[@pone.0228251.ref052]\]. Although the role of TBK1 (or other as-yet-unidentified ICOS-mediated downstream signaling pathways) has not been studied in the Treg population specifically, PI3K-independent signaling components such as these are important to consider when studying the role of ICOS signaling in relation to Treg expression of Foxp3 and CD25. Tregs have been shown to be exquisitely sensitive to levels of PI3K activation, where both too little PI3K activation and too much PI3K activation can negatively impact Treg survival and function through downregulation of Foxp3 expression \[[@pone.0228251.ref053], [@pone.0228251.ref054]\]. These results suggest that a balanced level of PI3K activation helps maintain Treg identity and function, but the complex signaling pathways that maintain this balanced PI3K activation in Treg cells remains to be described. Our results suggest that ICOS may promote this balanced level of PI3K activation, possibly through recruitment and activation of negative regulators of PI3K activation such as TBK1 \[[@pone.0228251.ref052]\]. Overall, understanding how the integration of all ICOS-mediated signals act in maintaining an effective Treg population remains an important area of study as it could provide potential insight into targets for manipulation in human disease.

Mutations in ICOS (or its ligand, ICOSL) in humans are part of a class of mutations leading to the development of common variable immunodeficiency (CVID) \[[@pone.0228251.ref016], [@pone.0228251.ref055], [@pone.0228251.ref056]\]. Patients with this immunodeficiency disorder are typically diagnosed following recurrent bacterial infections and present with severely decreased circulating class-switched antibody \[[@pone.0228251.ref016], [@pone.0228251.ref055], [@pone.0228251.ref057], [@pone.0228251.ref058]\]. Interestingly, however, despite being classified as an immunodeficiency disease, about 20% of patients also present with symptoms of autoimmunity \[[@pone.0228251.ref059]\]. Though the pathogenesis of this autoimmunity still remains largely unclear, abnormalities in the T cell compartment including expansion of antigen-experienced effector T cells, increased inflammatory cytokine production, and loss of IL-10-producing Tregs have been reported, which could contribute to dysregulation of immune responses and play a role in the autoimmune complications seen in this disease \[[@pone.0228251.ref060]--[@pone.0228251.ref067]\]. Further understanding of potential autoimmune manifestations in this disease remains an important open question, and our results suggest that the integration of PI3K-dependent and PI3K-independent ICOS signals in the Treg population could potentially play an important role in maintaining immune homeostasis.

The authors would like to thank all the members of the Harris lab, as well as graduate committee members Dr. Kenneth Tung, Dr. Ulrike Lorenz, Dr. Loren Erickson, and Dr. Young Hahn for their insightful comments and discussion during the preparation of this work. We would also like to thank Marieke K. Jones for her helpful input regarding relevant statistical analysis and coding, as well as Dr. Daniel Campbell for his generosity in sharing both ICOS KO and ICOS Y^181^F mice.
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Review Comments to the Author

The major concern with this paper are results in Figure 2, where the total ICOS KO phenocopies the WT strain whereas the ICOS YF mutant display decreased FoxP3 MFI and decreased CD25 expression on Treg. This is difficult or impossible to understand, since the ICOS KO clearly must also be defective in ICOS-triggered PI-3K signaling. The authors conclude in the Abstract and elsewhere that these findings \"suggest PI3K-independent effects of ICOS on Treg phenotype\", but this is not in line with their data showing an effect of abolishing PI-3K signaling on Treg phenotype. This discrepancy must be resolved.

We agree with the reviewer that this is a surprising result! Nevertheless, it was a robust and reproducible observation. We hypothesize that although both ICOS KO and ICOS YF Tregs lack the ability to activate PI3K, ICOS YF Tregs presumably have other intact signaling pathways downstream of ICOS. We hypothesize that these pathways (which are abolished in ICOS KO Tregs) are what is impacting the ability of ICOS YF Tregs to maintain Foxp3 and CD25 in the context of the inflamed brain. For this reason, we expect these particular results to be of interest to researchers that study ICOS signaling.

Other concerns:

Fig. 1C. Show percent positive Bcl-2 in addition to MFI.

All effector T cells in the brain during chronic infection express some level of Bcl-2, therefore the percent positive for all genotypes is 100%. However, the levels of Bcl-2 expression on a per-cell basis changes in the CD4+ effector T cell compartment in ICOS KO and ICOS YF mice. Representative histograms of Bcl-2 expression are now included in Figure 1G for clarity.

Fig. 2A-D. Show also absolute numbers of FoxP3+ cells in addition to percentages. Since the FoxP3- cell number is expanded in the mutant mice, it is possible that there is no difference on Treg number.

We agree with the reviewer that absolute number and percentages are relevant regarding Tregs. The requested data are now included in Figure 2E and described in the text in lines 295-6.

Fig. 3. The dramatic effect of ICOS on antibody responses is striking, but no direct evidence is provided that this results in increased susceptibility show in the figure. The authors could determine whether anti-serum infusion corrected the decrease in resistance.

We agree with the reviewer that we have not directly implicated antibody defects in the control of cyst burden. For this manuscript, we are reporting the similarities and differences between ICOS KO and ICOS YF mice during infection with T. gondii. We do not feel that we overstated our results and contend that it is merely our hypothesis that antibody defects are resulting in increased cyst burdens.

Reviewer \#2: In this report, Taije and colleagues investigated the role of ICOS signalling via PI3K during Toxoplasma gondii infection. This is an extension to their original studies, recently published in the Journal of immunology (O'Brien CA et al., 2019). In the present study, their findings suggest that this signalling pathway may be important in supporting regulatory T cell homeostasis. Their studies are technically sound and may be important for the readership at PLoS One. Some minor changes to the current text and figures may improve the quality of this manuscript for publication purposes.

Figures:

1\. The authors should consider adding representative flow cytometry plots of the data presented in data in figure one.

We agree that the flow plots add more information for the reader. These data are now included in Figure 1C, Figure 1E, and Figure 1G.

2\. Axis labels should be added to FACS plots presented in figure 2A-C.

Axis labels have been added to these plots for increased clarity.

3\. Axis labels should be added to FACS plots presented in figure 4A and 4C.

Axis labels have been added to these plots for increased clarity.

Text:

The authors should consider removing figure legends from the main text of the manuscript. These should go to a separate section.

The figure legends have now been embedded in the Results section as per PLoS One guidelines.

Minor scientific comment

Did the authors measure inflammatory cytokines in the brains of WT and ICOSKO/YF mice? In addition, did the authors examine the phenotype of the effector cells recruited to the brains during infection. If so, this data may be a good addition to the manuscript.

We agree that an analysis of the effector T cells is also of great interest. Because we observed changes in CD25 and Bcl-2 expression in our 2019 publication, we examined the number of effector T cells in the brain along with their expression of CD25 and Bcl-2. We have not examined cytokine production, but expect results to be similar to anti-ICOSL treatment, where IFN-� production does not change on a per cell basis, but there is an increase in effector cells in the brain leading to an overall increase in cytokine production.

Reviewer \#3: The authors present a study to understand the role of ICOS in response to chronic T. gondii infection. Two mutant mouse models are used, one full knock-out and one with a single amino acid substitution (Y to F) to prevent the recruitment and activation of PI3K. Results found that the overall T-cell numbers in the brain is increased in both mutant mouse lines after T. gondii infection, although the number of Treg cells were reduced. Both mutations caused a lack of an antibody response to T. gondii, which in turn, resulted in a higher brain cyst burden. The major differences between the KO and YF mutants were the reduction of Foxp3 expression on Treg cells and the number of CD25+ Treg cells, both of which were reduced in the YF compared to the full KO.

Major Comments:

1\. Clarify why it's stated (lines 294-295) that Foxp3 defects are only in Treg cells of the brain, when they show they are reduced in brain and spleen (Fig 2E and H).

We thank the reviewer for pointing out the lack of clarity in the text regarding these results. The text describing these results has now been changed to describe in more detail the Treg defects in the brain and spleen in lines 316-329.

2\. The authors state multiple times in the results (e.g. Lines 256 and 291) that CD25 expression levels are changing, however, that data is not shown. Data in Fig 2 shows the percentage of CD25+ cells but not the intensity of their expression. The data and/or text needs to be changed to match one another.

The data showing the MFI of CD25+ Tregs in both the brain and spleen are now included in Figure 2H and Figure 2L, respectively. These results are described in the text in lines 316-325.

3\. To go along with the cyst data (Fig 3), authors should show if either of the mouse mutations have an effect on the survival or health of the mice up to chronic infection.

Though both ICOS KO and ICOS YF mice survived the acute stage of infection and the early chronic phase in our hands, we did observe increased sickness in these mice compared to WT (increased ruffled fur, less activity), suggesting that the inability to control parasite burden in the brain might lead to survival defects in later chronic stages of infection.

4\. It's interesting that lack of PI3K signaling reduced Foxp3 expression and CD25 expressing cells but the KO did not, since this mutation also lacks the PI3K signaling. Although this starts to get explained in the discussion, more clarification as to how lacking both PI3K and the other potential cytoplasmic signaling can revert the phenotype back to wild type, since this is all on one protein can be a little counterintuitive.

It has been suggested in the literature that Tregs are very sensitive to PI3K activation levels, where too much or too little PI3K activation can negatively impact their survival and function (Abu-Eid, et al., 2014 & Sauer, et al. 2008). It is possible that the additional signaling pathways downstream of ICOS besides PI3K (which are intact in ICOS YF Tregs) serve as a pathway to negatively regulate activation of PI3K, as has been shown in Tfh cells (Pedros, et al. 2016). If this is true in Tregs, WT Tregs might recruit and activate PI3K downstream of ICOS, but also activate these negative regulatory pathways that prevent "too much" PI3K activation, leading to balanced PI3K activation in the Treg. In ICOS YF Tregs, the inability to activate PI3K is lost, so only these potential negative pathways are activated downstream of ICOS. If only these pathways are activated downstream of ICOS in ICOS YF Tregs, they might negatively impact PI3K too much, leading to too little PI3K activation, with has also been shown to decrease Treg Foxp3 expression. In ICOS KO Tregs, both the positive PI3K signal and the negative signal are lost, meaning the "balance" is maintained enough (possibly through other PI3K activating signals that can compensate for the loss of ICOS such as TCR/MHC, CD28, or IL-2) for ICOS KO Tregs to maintain Foxp3 and CD25 expression in the inflamed brain. Additional comments regarding this hypothesis have been added to the discussion in lines 464-472.

Minor Comments:

1\. References as to how the mutations were generated need to be included in the methods, or more clearly stated elsewhere in the text.

References to the original papers describing the generation of these mice have been added to the Methods section (line 109).

2\. Definitions of BMNC and MFI are never stated.

These terms have been defined in the Figure Legend for Figure 1 (lines 213 and 216-7, respectively).

3\. Figure 1A: should have "CD8+" (missing the + symbol in the panel).

This has been added to Figure 1A.

4\. Figure 2A-C: Label the graph axes.

Axis labels have been added to flow plots for clarity.

5\. Figure 2D-F: For clarity and consistency, label these as being from the brain.

The graphs in in Figure 2D-F have now been labeled as showing data from the brain.

6\. Figure 4: Label axes of the flow graph

Axis labels have been added to these flow plots for increased clarity.
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We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. We also ask that you add a comment about the seemingly paradoxical result of a Treg phenotype in ICOS YF mice, but no phenotype in KO cells, as suggested by reviewers 1 and 3. Also please add axis labels to figure 4 A and C. 
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

Reviewer \#3: Yes
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have addressed most of the reviewers\' comments satisfactorily. My only issue remains with the seemingly paradoxical result that the authors report no Treg phenotype with ICOS KO but a phenotype with the ICOS YF mice. The authors provide a nice explanation of why this might be the case in the response to reviewer 3, but it is still glossed over in the manuscript. I suggest that the authors incorporate their response to the reviewer in the manuscript discussion.

Reviewer \#2: I am satisfied with authors\' responses to my comments. Therefore, I have no further concerns on this submission.

Reviewer \#3: The authors did a great job addressing many of the review concerns, though I have two comments I would like addressed further.

1\. I would like to see the author comments addressing Reviewer 3 Major Comment 3 added to the text of the manuscript (I believe even stating the phenotype with "data not shown" would be sufficient). I believe this information would be beneficial to the Toxoplasma community since the mice survive infection while lacking antibodies. Also, it is important to know that many of the mice survived so that we know that the data is not skewed by looking at only the rare mouse that happened to live to the chronic stage.

2\. Panels Figure 4 A and C do not have axis labels. Please label for clarification.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

10.1371/journal.pone.0228251.r004

Acceptance letter

Knoll

Laura J.

Academic Editor

© 2020 Laura J. Knoll

2020

Laura J. Knoll

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

16 Jan 2020

PONE-D-19-26867R1

ICOS-deficient and ICOS YF mutant mice fail to control *Toxoplasma gondii* infection of the brain

Dear Dr. Harris:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Laura J. Knoll

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Current address: Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America
